ReviewFrontline gastroenterology2018
Practical guidance on the use of faecal calprotectin.
Review in Frontline gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Systematic review: outcomes and adverse events from randomised trials in Crohn's disease.Alimentary pharmacology & therapeutics · 2019Pooled it
- Article
- Unveiling phytoconstituents and the anti-inflammatory potential of Crassula tetragona L. in ulcerative colitis: A focus on the PPARγ/SIRT1 axis.Inflammopharmacology · 2026Article
- Cohort profile: the Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD).BMJ open · 2025Article
- Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Evaluating the significance of ECSCR in the diagnosis of ulcerative colitis and drug efficacy assessment.Frontiers in immunology · 2024Article
- Recent developments in the assessment and management of inflammatory bowel disease in childhood: a narrative review.Translational pediatrics · 2023Review
- S-100 Proteins: Basics and Applications as Biomarkers in Animals with Special Focus on Calgranulins (S100A8, A9, and A12).Biology · 2023Review
- Identification of gene signatures associated with ulcerative colitis and the association with immune infiltrates in colon cancer.Frontiers in immunology · 2023Article
- Integrated Analysis of Multiple Microarray Studies to Identify Novel Gene Signatures in Ulcerative Colitis.Frontiers in genetics · 2021Article
- The Increased Levels of Fecal Calprotectin in Children With Active Enthesitis Related Arthritis and MRI Signs of Sacroiliitis: The Results of a Single Center Cross-Sectional Exploratory Study in Juvenile Idiopathic Arthritis Patients.Frontiers in medicine · 2021Article
- Identification of differentially expressed genes in ulcerative colitis and verification in a colitis mouse model by bioinformatics analyses.World journal of gastroenterology · 2020Article
- Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study.Intestinal research · 2020Article
- Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions.Inflammatory bowel diseases · 2020Article
- Biotin Supplementation Ameliorates Murine Colitis by Preventing NF-κB Activation.Cellular and molecular gastroenterology and hepatology · 2020Article
- Faecal calprotectin determination: impact of preanalytical sample treatment and stool consistency on within- and between-method variability.Biochemia medica · 2019Article
- Testing, testing.Frontline gastroenterology · 2018Article
- Diagnostic Markers for Nonspecific Inflammatory Bowel Diseases.Disease markers · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differentiation between inflammatory bowel disease (IBD) and functional gut disorders, and the determination of mucosal disease activity in established cases of IBD remain the cornerstones of disease diagnosis and management. Non-invasive, accurate biomarkers of gut inflammation are needed due to the variability of symptoms, the inaccuracies of currently available blood markers and the cost and invasive nature of endoscopy. Numerous biomarkers have been used and/or considered with some in current use. This article reviews the current evidence base around the indications for using biomarkers and their limitations, with a particular focus on faecal calprotectin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.